Protein Polymer Announces the Completion of Private Placement of Common
Stock with J&J and other Investors
J&J's Investment Related to Previously Announced Extension of Collaboration with Ethicon to Develop and Commercialize Surgical Wound Closure Products
SAN DIEGO, Jan. 7, 1997 -- Protein Polymer Technologies, Inc.
(Nasdaq: PPTI), today announced the completion of a $4,760,000 private
placement of 1,904,000 shares of PPTI Common stock with
(JJDC), and other institutional investors. The investors paid $2.50 per
share of common stock. JJDC's equity investment was related to an earlier
announcement of an extension of the collaboration between Ethicon, Inc., a
subsidiary of Johnson & Johnson, and PPTI to jointly develop and commercialize
surgical tissue adhesives and sealants for wound closure and related surgical
applications.
The shares have not been registered under the Securities Act and may not
be offered or sold in the United States absent registration or an applicable
exemption from registration requirements; however the Company has agreed with
the investors to file a registration statement with the SEC later this month
to register any resales of the shares. Any offering relative to such resales
will be made only by means of a prospectus.
In an unrelated matter, the Company announced that it has retained the
investment banking firm of Hambrecht & Quist LLC as its financial advisor to
aid the Company in a review of its strategic operating and financial goals.
Protein Polymer Technologies, Inc. is a development stage biomaterials
company focused on tissue repair and drug delivery. In addition to tissue
adhesives and sealants, other products being developed include materials for
wound healing and tissue augmentation, surgical adhesion barriers, and drug
delivery devices. PPTI also markets a line of protein polymer-activated cell
culture products under the trade names of ProNectin(R) and SmartPlastic(R). |